Safety of Long-Term Proactive Management with Fixed-Dose Combination Calcipotriene 0.005% and Betamethasone Dipropionate 0.064% Foam in Patients with Psoriasis Vulgaris: Results of a Phase III, Multicentre, Randomized, 52-Week, Vehicle-Controlled Trial. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 4, n. 5, p. s31, 2020. DOI: 10.25251/skin.4.supp.31. Disponível em: https://skin.dermsquared.com/skin/article/view/980. Acesso em: 22 may. 2026.